291 related articles for article (PubMed ID: 32260326)
1. Blocking Myc to Treat Cancer: Reflecting on Two Decades of Omomyc.
Massó-Vallés D; Soucek L
Cells; 2020 Apr; 9(4):. PubMed ID: 32260326
[TBL] [Abstract][Full Text] [Related]
2. Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy.
Beaulieu ME; Jauset T; Massó-Vallés D; Martínez-Martín S; Rahl P; Maltais L; Zacarias-Fluck MF; Casacuberta-Serra S; Serrano Del Pozo E; Fiore C; Foradada L; Cano VC; Sánchez-Hervás M; Guenther M; Romero Sanz E; Oteo M; Tremblay C; Martín G; Letourneau D; Montagne M; Morcillo Alonso MÁ; Whitfield JR; Lavigne P; Soucek L
Sci Transl Med; 2019 Mar; 11(484):. PubMed ID: 30894502
[TBL] [Abstract][Full Text] [Related]
3. The action mechanism of the Myc inhibitor termed Omomyc may give clues on how to target Myc for cancer therapy.
Savino M; Annibali D; Carucci N; Favuzzi E; Cole MD; Evan GI; Soucek L; Nasi S
PLoS One; 2011; 6(7):e22284. PubMed ID: 21811581
[TBL] [Abstract][Full Text] [Related]
4. Tumor penetrating peptides inhibiting MYC as a potent targeted therapeutic strategy for triple-negative breast cancers.
Wang E; Sorolla A; Cunningham PT; Bogdawa HM; Beck S; Golden E; Dewhurst RE; Florez L; Cruickshank MN; Hoffmann K; Hopkins RM; Kim J; Woo AJ; Watt PM; Blancafort P
Oncogene; 2019 Jan; 38(1):140-150. PubMed ID: 30076412
[TBL] [Abstract][Full Text] [Related]
5. OmoMYC blunts promoter invasion by oncogenic MYC to inhibit gene expression characteristic of MYC-dependent tumors.
Jung LA; Gebhardt A; Koelmel W; Ade CP; Walz S; Kuper J; von Eyss B; Letschert S; Redel C; d'Artista L; Biankin A; Zender L; Sauer M; Wolf E; Evan G; Kisker C; Eilers M
Oncogene; 2017 Apr; 36(14):1911-1924. PubMed ID: 27748763
[TBL] [Abstract][Full Text] [Related]
6. Omomyc Reveals New Mechanisms To Inhibit the MYC Oncogene.
Demma MJ; Mapelli C; Sun A; Bodea S; Ruprecht B; Javaid S; Wiswell D; Muise E; Chen S; Zelina J; Orvieto F; Santoprete A; Altezza S; Tucci F; Escandon E; Hall B; Ray K; Walji A; O'Neil J
Mol Cell Biol; 2019 Nov; 39(22):. PubMed ID: 31501275
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Myc transcriptional activity by a mini-protein based upon Mxd1.
Demma MJ; Hohn MJ; Sun A; Mapelli C; Hall B; Walji A; O'Neil J
FEBS Lett; 2020 May; 594(10):1467-1476. PubMed ID: 32053209
[TBL] [Abstract][Full Text] [Related]
8. Myc and Omomyc functionally associate with the Protein Arginine Methyltransferase 5 (PRMT5) in glioblastoma cells.
Mongiardi MP; Savino M; Bartoli L; Beji S; Nanni S; Scagnoli F; Falchetti ML; Favia A; Farsetti A; Levi A; Nasi S; Illi B
Sci Rep; 2015 Nov; 5():15494. PubMed ID: 26563484
[TBL] [Abstract][Full Text] [Related]
9. Computational insights into the differentiated binding affinities of Myc, Max, and Omomyc dimers to the E-boxes of DNA.
Dai Y; Zhang J; Wang Y; Liu L; Gao J
J Mol Model; 2022 Sep; 28(10):329. PubMed ID: 36149511
[TBL] [Abstract][Full Text] [Related]
10. Design and properties of a Myc derivative that efficiently homodimerizes.
Soucek L; Helmer-Citterich M; Sacco A; Jucker R; Cesareni G; Nasi S
Oncogene; 1998 Nov; 17(19):2463-72. PubMed ID: 9824157
[TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of compound NSC13728 as Omomyc homodimer stabilizer by molecular dynamics simulation and MM/GBSA free energy calculation.
Gao J; Wang Y; Li K; Zhang J; Geng X
J Mol Model; 2022 Mar; 28(4):92. PubMed ID: 35294626
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice.
Soucek L; Whitfield JR; Sodir NM; Massó-Vallés D; Serrano E; Karnezis AN; Swigart LB; Evan GI
Genes Dev; 2013 Mar; 27(5):504-13. PubMed ID: 23475959
[TBL] [Abstract][Full Text] [Related]
13. Omomyc, a potential Myc dominant negative, enhances Myc-induced apoptosis.
Soucek L; Jucker R; Panacchia L; Ricordy R; Tatò F; Nasi S
Cancer Res; 2002 Jun; 62(12):3507-10. PubMed ID: 12067996
[TBL] [Abstract][Full Text] [Related]
14. Omomyc expression in skin prevents Myc-induced papillomatosis.
Soucek L; Nasi S; Evan GI
Cell Death Differ; 2004 Sep; 11(9):1038-45. PubMed ID: 15143346
[TBL] [Abstract][Full Text] [Related]
15. Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc.
Madden SK; de Araujo AD; Gerhardt M; Fairlie DP; Mason JM
Mol Cancer; 2021 Jan; 20(1):3. PubMed ID: 33397405
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of cancer cell growth and c-Myc transcriptional activity by a c-Myc helix 1-type peptide fused to an internalization sequence.
Giorello L; Clerico L; Pescarolo MP; Vikhanskaya F; Salmona M; Colella G; Bruno S; Mancuso T; Bagnasco L; Russo P; Parodi S
Cancer Res; 1998 Aug; 58(16):3654-9. PubMed ID: 9721875
[TBL] [Abstract][Full Text] [Related]
17. MYC as a target for cancer treatment.
Duffy MJ; O'Grady S; Tang M; Crown J
Cancer Treat Rev; 2021 Mar; 94():102154. PubMed ID: 33524794
[TBL] [Abstract][Full Text] [Related]
18. Multiple Synthetic Routes to the Mini-Protein Omomyc and Coiled-Coil Domain Truncations.
Brown ZZ; Mapelli C; Farasat I; Shoultz AV; Johnson SA; Orvieto F; Santoprete A; Bianchi E; McCracken AB; Chen K; Zhu X; Demma MJ; Lacey BM; Canada KA; Garbaccio RM; O'Neil J; Walji A
J Org Chem; 2020 Feb; 85(3):1466-1475. PubMed ID: 31660743
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Myc effectively targets KRAS mutation-positive lung cancer expressing high levels of Myc.
Fukazawa T; Maeda Y; Matsuoka J; Yamatsuji T; Shigemitsu K; Morita I; Faiola F; Durbin ML; Soucek L; Naomoto Y
Anticancer Res; 2010 Oct; 30(10):4193-200. PubMed ID: 21036740
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of cMYC-MAX transcription factors hetero-dimerization with structurally engineered omoMYC to downregulate oncogenic pathways in renal carcinoma.
Li W; Bano F; Khan A; Wei DQ; Alshammari A; Xu B; Wang Y
Comput Biol Med; 2023 Sep; 164():107257. PubMed ID: 37527610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
